阻塞型睡眠呼吸中止症：競爭格局與臨床試驗分析，2026 年

阻塞型睡眠呼吸中止症（OSA）是一種常見的睡眠相關呼吸障礙，其特徵是睡眠期間上呼吸道反覆出現部分或完全阻塞。這些阻塞會導致呼吸中止或呼吸不足，進而引起間歇性血氧飽和度下降、睡眠片段化和反覆覺醒。 OSA與白天過度嗜睡、疲勞、認知功能障礙以及心血管和代謝併發症風險增加有關。

阻塞性睡眠呼吸中止症（OSA）是由上呼吸道解剖和生理因素共同作用導致的，這些因素會增加睡眠期間氣道阻塞的風險。主要危險因子包括肥胖、高齡、男性、頸圍增大、顱顏畸形、閉經、家族病史、吸菸和鼻塞。頸部脂肪過多會使上呼吸道變窄，增加睡眠期間氣道阻塞的傾向。

睡眠期間，上呼吸道肌肉活動減弱會導致易感人群的呼吸道狹窄或阻塞。這會導致反覆出現呼吸暫停和低通氣，隨後出現氧飽和度下降、二氧化碳積聚，以及短暫覺醒以恢復氣道通暢。反覆的間歇性低氧和睡眠片段化會增加交感神經系統活性、氧化壓力和炎症，從而導致心血管和代謝併發症。

診斷包括臨床評估和客觀睡眠研究。整夜多導睡眠圖（PSG）是標準的診斷方法，可測量睡眠期間的氣流、呼吸努力、血氧飽和度、腦電圖（EEG）和其他生理參數。呼吸暫停低通氣指數（AHI）用於評估疾病的嚴重程度。每小時5-15次呼吸中止低通氣事件被認為是輕度阻塞性睡眠呼吸中止症（OSA），每小時15-30次被認為是中度OSA，每小時30次或更多被認為是重度OSA。在某些情況下，也可以進行居家睡眠呼吸中止症檢測。

治療目標是維持呼吸道通暢，減少呼吸事件，改善症狀和生活品質。持續性呼吸道正壓通氣（CPAP）是主要治療方法，特別適用於中重度阻塞性睡眠呼吸中止症（OSA），可預防睡眠期間呼吸道阻塞。其他治療方案，根據疾病嚴重程度、解剖結構、合併症和治療耐受性而定，包括體重管理、下顎前突矯正器、雙水平氣道正壓通氣（BiPAP）和手術介入。

報告要點：

• 2026年7月，Apnimed公司宣布，美國食品藥物管理局（FDA）已接受其用於治療成人阻塞型睡眠呼吸中止症的藥物AD109（阿洛昔布寧2.3毫克/阿托莫西汀75毫克）的新藥認證申請（NDA）。 FDA依據「處方藥使用者收費法案」（「PDUFA」）將審查完成日期定為2027年2月28日。
• 2026 年 6 月，Incannex Healthcare Inc. 宣布，美國專利商標局 (USPTO) 授予其一項名為「阻塞型睡眠呼吸中止症的治療方法和組合物」的關鍵專利。
• 2026年5月，Apnimed公司宣布兩篇關於AD109（阿洛昔布寧2.5毫克/阿托莫西汀75毫克）的同儕審查論文同時發表。 AD109是一種在研口服片劑，每日睡前服用一次，旨在改善氧合，並針對阻塞型睡眠呼吸中止症（OSA）的神經肌肉根源。 III期SynAIRgy試驗的結果發表於「美國呼吸與重症監護醫學雜誌」（AJRCCM），同時發表於「美國呼吸細胞與分子生物學雜誌」（AJRCMB）的一篇相關機制綜述也重點闡述了AD109的神經肌肉臨床實驗機制以及直接促成III期臨床試驗設計和成功的生物學原理。
• 2025 年 12 月，Incannex Healthcare Inc. 宣布，美國食品藥物管理局(FDA) 已授予其口服固定劑量組合藥物候選 IHL-42X簡審類，用於治療阻塞型睡眠呼吸中止症(OSA)。
• 2025年5月，Mosanna Therapeutics宣布完成8,000萬美元A輪資金籌措。該公司致力於研發易於使用的夜間鼻噴霧，用於治療阻塞型睡眠呼吸中止症，幫助恢復人體自然的呼吸道控制功能。資金籌措由Pivotal bioVenture Partners和EQT Life Sciences主導，Forbion、Broadview Ventures和Norwest擔任聯席領投方。現有投資者包括創始投資者Forty51 Ventures，以及Supermoon Capital和High-Tech Grunderfonz (HTGF)。該公司也宣布，將資金籌措來推進其MOS118的II期臨床試驗。
• 2025 年 1 月，Mineralis Therapeutics 宣布，其用於評估洛德司他（lorndrostat）對中度至重度阻塞型睡眠呼吸中止症（ OSA）和高血壓患者的治療效果的 II 期臨床試驗的研究藥物申請（IND）已獲得美國食品藥物管理局（FDA）的批准。

目錄

介紹

摘要整理

阻塞型睡眠呼吸中止症：概述

• 病因和風險因素
• 病理生理學
• 診斷
• 治療

阻塞型睡眠呼吸中止症：分析觀點—詳細的市場評估

• 阻塞型睡眠呼吸中止症市場：按公司分類的合作關係分析

競爭格局

• 對各公司進行比較評估（依治療領域及研發階段）

阻塞型睡眠呼吸中止症：公司和產品簡介（已上市治療方案）

• Eli Lilly and Company
  • 公司簡介
• Zeppbound
  • 產品概述
  • 研究與開發活動
  • 產品開發活動

阻塞型睡眠呼吸中止症：公司簡介和產品概述（治療方案正在研發中）

• 後期研發產品（III期）
  • 比較分析
  • Amgen
    • 公司簡介
  • 馬利巴特·卡夫拉·庫魯奇德
    • 產品概述
    • 研究與開發活動
    • 產品開發活動
• 中期產品（II期和III期）
  • 比較分析
  • Incannex Healthcare
    • 公司簡介
  • IHL-42X
    • 產品概述
    • 研究與開發活動
    • 產品開發活動
• 早期產品（I期）
  • 比較分析
  • Mosanna Therapeutics
    • 公司簡介
  • MOS118
    • 產品概述
    • 研究與開發活動
    • 產品開發活動
• 臨床前階段產品
  • 比較分析
• 處於藥物發現階段的產品
  • 比較分析
• 產品處於未知的開發階段
  • 比較分析

治療評估

• 評分：依產品類型
• 評分：依階段和產品類型
• 評估：透過給藥途徑
• 評估：按管理階段和途徑
• 評估：按分子類型
• 評估：依疾病分期和分子類型

臨床試驗評估

臨床試驗分析

• 評估：視情況而定
• 評估：發展狀況和階段
• 評估：依終點狀態
• 評估：按年齡層和登記患者人數進行評估
• 評估：依研究完成年份

臨床試驗設計與分析

• 評估：透過臨床試驗中的受試者分配進行評估
• 評估：透過臨床試驗中的介入模型進行評價
• 評估：以登記患者的身份和人數進行評估
• 評估：透過臨床試驗中的盲法進行評價

贊助和區域分析

• 評分：由主要贊助商提供
• 評估：按國家/地區和階段，按贊助臨床試驗總數進行評估
• 評估：按國家和臨床治療進行評估

已停產產品

• 比較分析

阻塞型睡眠呼吸中止症：未滿足的需求

阻塞型睡眠呼吸中止症：市場促進因素與障礙

DelveInsight's, "Obstructive Sleep Apnea - Competitive Landscape and Clinical Trial Analysis, 2026," report provides comprehensive insights about 18+ companies and 20+ drugs in Obstructive Sleep Apnea Competitive landscape. It covers the therapeutics assessment by product type, stage, route of administration, and molecule type. It further highlights the inactive pipeline products in this space.

Geography Covered:

• Global coverage

Obstructive Sleep Apnea: Understanding

Obstructive Sleep Apnea: Overview

Obstructive sleep apnea (OSA) is a common sleep-related breathing disorder characterized by repeated partial or complete blockage of the upper airway during sleep. These episodes cause apnea or hypopnea, resulting in intermittent oxygen desaturation, sleep fragmentation, and repeated arousals. OSA is associated with excessive daytime sleepiness, fatigue, impaired cognition, and an increased risk of cardiovascular and metabolic complications.

OSA results from a combination of upper-airway anatomy and physiological factors that increase airway collapsibility during sleep. Major risk factors include obesity, older age, male sex, increased neck circumference, craniofacial abnormalities, menopause, family history, smoking, and nasal congestion. Excess fat around the neck can narrow the upper airway and increase its tendency to collapse during sleep.

During sleep, reduced activity of the upper-airway muscles can cause the airway to narrow or collapse in susceptible individuals. This leads to repeated episodes of apnea or hypopnea, followed by oxygen desaturation, carbon dioxide accumulation, and brief arousals that restore airway patency. Recurrent intermittent hypoxia and sleep fragmentation can increase sympathetic activity, oxidative stress, and inflammation, contributing to cardiovascular and metabolic complications.

Diagnosis involves clinical assessment followed by objective sleep testing. Overnight polysomnography (PSG) is the standard diagnostic test and measures airflow, respiratory effort, oxygen saturation, brain activity, and other physiological parameters during sleep. The apnea-hypopnea index (AHI) is used to assess disease severity: 5-<15 events/hour indicates mild OSA, 15-<30 indicates moderate OSA, and >=30 indicates severe OSA. Home sleep apnea testing may also be used in selected patients.

Treatment aims to maintain airway patency, reduce respiratory events, and improve symptoms and quality of life. Continuous positive airway pressure (CPAP) is the main treatment, particularly for moderate-to-severe OSA, as it prevents airway collapse during sleep. Other options include weight management, mandibular advancement devices, BiPAP, and surgical interventions, depending on disease severity, anatomy, comorbidities, and treatment tolerance.

Report Highlights:

• In July 2026, Apnimed, Inc. announced that the U.S. Food and Drug Administration ("FDA") has accepted for review the New Drug Application filing of AD109 (aroxybutynin 2.3 mg/atomoxetine 75 mg) for the treatment of adults with obstructive sleep apnea. The FDA has assigned a Prescription Drug User Fee Act ("PDUFA") target action date of February 28, 2027.
• In June 2026, Incannex Healthcare Inc. announced that the United States Patent and Trademark Office (USPTO) has granted a key patent titled "Compositions and Methods of Treatment for Obstructive Sleep Apnea."
• In May 2026, Apnimed Inc. announced the simultaneous publication of two peer-reviewed articles on AD109 (aroxybutynin 2.5 mg/atomoxetine 75 mg), an investigational, once-daily oral pill taken at bedtime designed to improve oxygenation and target the neuromuscular root cause of obstructive sleep apnea (OSA). The Phase III SynAIRgy trial results were published in the American Journal of Respiratory and Critical Care Medicine (AJRCCM), alongside a companion mechanistic review article in the American Journal of Respiratory Cell and Molecular Biology (AJRCMB) that highlighted AD109's neuromuscular mechanism of action and the biological rationale that directly informed the design and success of the Phase III program.
• In December 2025, Incannex Healthcare Inc. announced that the US Food and Drug Administration (FDA) has granted Fast Track designation for IHL-42X, the Company's oral fixed-dose combination product candidate for the treatment of obstructive sleep apnea (OSA).
• In May 2025, Mosanna Therapeutics, announced the close of USD 80 million in Series A funding. The company is developing an easy-to-use nighttime nasal spray to treat obstructive sleep apnea that will help restore the body's natural airway control. The financing was led by Pivotal bioVenture Partners and EQT Life Sciences, along with Forbion, Broadview Ventures and Norwest as co-lead investors. Returning investors included founding investor Forty51 Ventures, as well as Supermoon Capital and High-Tech Grunderfonds (HTGF). The company has also announced that this series A funding to advance MOS118 through Phase II clinical trials.
• In January 2025, Mineralys Therapeutics announced that the U.S. Food and Drug Administration (FDA) has cleared the Company's Investigational New Drug (IND) Application for a Phase II clinical trial to evaluate the effect of lorundrostat in the treatment of subjects with moderate-to-severe obstructive sleep apnea (OSA) and hypertension.

Obstructive Sleep Apnea: Company and Product Profiles (Marketed Therapies)

1. Company Overview: Eli Lilly and Company

Eli Lilly and Company is a global pharmaceutical company headquartered in Indianapolis, Indiana, U.S., founded in 1876. The company focuses on discovering, developing, manufacturing, and delivering medicines aimed at addressing major health challenges. Lilly conducts research and clinical development globally and has a portfolio spanning areas including diabetes, obesity, oncology, immunology, neuroscience, and other diseases. The company's mission is to create medicines that make life better for people around the world, with innovation and pharmaceutical research at the core of its activities.

Product Description: Zepbound

Zepbound (Tirzepatide) is a dual GIP (glucose-dependent insulinotropic polypeptide) and GLP-1 (glucagon-like peptide-1) receptor agonist developed by Eli Lilly and Company. It acts by activating GIP and GLP-1 receptors, which helps reduce appetite and food intake, leading to significant body-weight reduction. For obstructive sleep apnea (OSA), its therapeutic effect is primarily associated with weight loss, which can reduce upper-airway obstruction during sleep and consequently decrease the frequency of apnea and hypopnea events. The U.S. FDA approved tirzepatide in December 2024 for the treatment of moderate-to-severe OSA in adults with obesity, making it the first FDA-approved medication specifically for OSA.

Obstructive Sleep Apnea: Company and Product Profiles (Pipeline Therapies)

1. Company Overview: Apnimed

Apnimed is a privately held late stage clinical pharmaceutical company dedicated to the discovery, development and commercialization of novel oral therapies that address the neurobiology of sleep-related breathing diseases. The company believes the introduction of once-nightly oral drugs has the potential to expand diagnosis and the reach of treatment for people with OSA. Also the company believes that people with OSA would benefit from having multiple drugs with differing mechanisms to more fully address the heterogeneity of OSA's disease pathophysiology. Apnimed envisions a new era where novel oral therapies simplify intervention, expand the reach of diagnosis and treatment, and help more people get the oxygen and restorative sleep needed to thrive.

Product Description: AD109

AD109 is investigational and is designed to be the first potential pharmacological treatment to improve oxygenation during sleep and target the neuromuscular root cause of upper airway collapse in people with OSA. It is a potentially first-in-class combination of aroxybutynin, a novel antimuscarinic, and atomoxetine, a selective norepinephrine reuptake inhibitor. AD109 is a once-daily oral pill taken at bedtime that is designed to lower the complexity of intervention and may help more people benefit from effective, restorative sleep. In a disease treatment landscape characterized by complex and invasive treatment options, AD109, if approved, may offer a convenient oral solution to help improve oxygenation and health for people living with OSA. The US Food and Drug Administration (FDA) assigned a Prescription Drug User Fee Act (PDUFA) target action date of February 28, 2027, for AD109 (aroxybutynin/atomoxetine), an investigational once-nightly oral pill developed by Apnimed to treat adults with obstructive sleep apnea.

2. Company Overview: Eli Lilly and Company

Eli Lilly and Company is a global medicine company headquartered in Indianapolis, Indiana, founded in 1876. The company focuses on discovering, developing, and delivering medicines intended to address significant health challenges and improve patient's lives. Lilly conducts research across multiple therapeutic areas and has a global presence, with clinical research conducted in more than 55 countries. Its research and development efforts are supported by a broad portfolio of innovative medicines and continued investment in the discovery and development of new treatments.

Product Description: Orforglipron

Orforglipron is a once-daily, oral, small-molecule (non-peptide) glucagon-like peptide-1 (GLP-1) receptor agonist developed by Eli Lilly. It acts by activating GLP-1 receptors, which helps reduce appetite and food intake, thereby supporting body-weight reduction. As a GLP-1 receptor agonist, it also improves glucose regulation by enhancing glucose-dependent insulin secretion and reducing glucagon secretion. Unlike injectable peptide-based GLP-1 therapies, orforglipron is an oral small molecule that can be taken without restrictions on food or water intake. Orforglipron was discovered by Chugai Pharmaceutical Co., Ltd. and licensed by Lilly in 2018. Currently, the drug is being evaluated in the Phase III stage of its development for the treatment of Sleep Apnea.

3. Company Overview: Incannex Healthcare

Incannex is leading the way in developing combination medicines that target the underlying biological pathways associated with chronic conditions, including obstructive sleep apnea, rheumatoid arthritis and generalized anxiety disorder. The company is advancing three clinical-stage product candidates based on evidence-based innovation and supported by streamlined operations. The company is advancing many clinical-stage product which include Incannex's lead clinical program, IHL-42X, is an oral fixed-dose combination of dronabinol and acetazolamide designed to target underlying mechanisms and act synergistically in the treatment of obstructive sleep apnea. Incannex is committed to advancing therapies that address multiple biological pathways with the goal of improving patient outcomes and creating long-term shareholder value.

Product Description: IHL-42X

IHL-42X is an oral fixed-dose combination therapy of dronabinol and acetazolamide designed to act synergistically by targeting two physiological mechanisms involved in OSA. Dronabinol, a synthetic form of delta-9-tetrahydrocannabinol (THC), acts on cannabinoid receptors and is intended to stimulate upper-airway dilation, thereby helping reduce airway obstruction during sleep. Acetazolamide, a carbonic anhydrase inhibitor, induces a mild metabolic acidosis, which signals increased carbon dioxide levels to the body and stimulates ventilation. By combining these mechanisms, IHL-42X is intended to address both upper-airway dysfunction and ventilatory control instability, thereby reducing the frequency of apneas and hypopneas, measured by the Apnea-Hypopnea Index (AHI). Currently the drug is in Phase II/III stage of its development for the treatment of Obstructive Sleep Apnea.

4. Company Overview: Mosanna Therapeutics

Mosanna Therapeutics is focused on developing a pharmaceutical approach to obstructive sleep apnea (OSA), with the goal of shifting treatment from external, mechanical intervention toward restoring the body's natural airway control during sleep. The company is developing an easy-to-use nighttime nasal spray designed to help restore the body's natural airway control and reactivate the upper airway muscles to keep the airway open. Mosanna describes its approach as working with the body's natural physiology rather than mechanically forcing the airway open.

Product Description: MOS118

MOS118 is an investigational intranasal small-molecule therapy developed by Mosanna Therapeutics for the treatment of obstructive Sleep Apnea (OSA). Administered as a bedtime nasal spray, MOS118 is designed to restore the body's natural upper airway reflexes by temporarily modulating the neuromuscular control of the throat and upper airway muscles, thereby reducing airway collapse during sleep and maintaining airway patency. Unlike mechanical therapies such as CPAP, MOS118 targets the underlying neuromuscular dysfunction associated with OSA through a non-invasive pharmacological approach. Currently, the drug is being evaluated in the Phase I stage of its development for the treatment of Sleep Apnea.

Obstructive Sleep Apnea Analytical Perspective by DelveInsight

• In-depth Commercial Assessment: Obstructive Sleep Apnea Collaboration Analysis by Companies

The Report provides in-depth commercial assessment of drugs that have been included, which comprises collaboration, agreement, licensing and acquisition - deals values trends. The sub-segmentation is described in the report which provide company-company collaboration (licensing/partnering), company academic collaboration and acquisition analysis in tabulated form.

• Obstructive Sleep Apnea Competitive Landscape

The report comprises of comparative assessment of Companies (by therapy, development stage, and technology).

Obstructive Sleep Apnea Report Assessment

• Company Analysis
• Therapeutic Assessment
• Pipeline Assessment
• Inactive drugs assessment
• Unmet Needs

Obstructive Sleep Apnea Clinical Trial Assessment

• Clinical Trial Analysis
• Clinical Trial Design Analysis
• Sponsor and Geographical Analysis
• Obstructive Sleep Apnea Clinical Trial Analysis

The report comprises of comparative assessment of clinical trial analysis (by status, development stage, therapy area, enrolled participants by age, study completion year, end point status).

• Obstructive Sleep Apnea Clinical Trial Design Analysis

The report comprises of comparative assessment of clinical trial design analysis (by allocation, interventional model, enrolled participants by status, masking).

• Sponsor and Geographical Analysis

The report comprises of comparative assessment of sponsor and geographical analysis (by top sponsors, developmental stage, clinical trials sponsored by countries, therapies by countries).

Key Questions:

Current Treatment Scenario and Emerging Therapies:

• How many companies are developing Obstructive Sleep Apnea drugs?
• How many Obstructive Sleep Apnea drugs are developed by each company?
• How many emerging drugs are in mid-stage, and late-stage of development for the treatment of Obstructive Sleep Apnea?
• What are the key collaborations (Industry-Industry, Industry-Academia), Mergers and acquisitions, licensing activities related to the Obstructive Sleep Apnea therapeutics?
• What are the recent trends, drug types and novel technologies developed to overcome the limitation of existing therapies?
• What are the clinical studies going on for Obstructive Sleep Apnea and their status?
• What are the key designations that have been granted to the emerging and approved drugs?

Key Players

• Eli Lilly and Company
• Apnimed
• Amgen
• Mosanna Therapeutics
• Mineralys Therapeutics Inc.
• Shionogi-Apnimed Sleep Science, LLC
• Incannex Healthcare Ltd
• Novo Nordisk
• Gan & lee pharmaceuticals
• Hangzhou Sciwind Biosciences Co., Ltd.
• Hengrui Pharma
• Kailera Therapeutics

Key Products

• Zepbound
• AD109
• Eloralintide
• Orforglipron
• Maridebart cafraglutide
• MOS118
• Lorundrostat
• SASS-001
• SASS-002 (sulthiame)
• IHL42X
• NNC0487-0111
• GZR18
• XW003
• Ribupatide injection (HRS9531, known as KAI-9531 outside Greater China)

Table of Contents

Introduction

Executive Summary

Obstructive Sleep Apnea: Overview

• Introduction
• Causes and Risk factors
• Pathophysiology
• Diagnosis
• Treatment

Obstructive Sleep Apnea -Analytical Perspective: In-depth Commercial Assessment

• Obstructive Sleep Apnea Collaboration Analysis by Companies

Competitive Landscape

• Comparative Assessment of Companies (by therapy, and development stage)

Obstructive Sleep Apnea: Company and Product Profiles (Marketed Therapies)

Eli Lilly and Company

• Company Overview

Zepbound

• Product Description
• Research and Development Activities
• Product Developmental Activities

Obstructive Sleep Apnea: Company and Product Profiles (Pipeline Therapies)

Late Stage Products (Phase III)

• Comparative Analysis

Amgen

• Company Overview

Maridebart cafraglutide

• Product Description
• Research and Development Activities
• Product Developmental Activities

Mid Stage Products (Phase II/III)

• Comparative Analysis

Incannex Healthcare

• Company Overview

IHL-42X

• Product Description
• Research and Development Activities
• Product Developmental Activities

Early Stage Products (Phase I)

• Comparative Analysis

Mosanna Therapeutics

• Company Overview

MOS118

• Product Description
• Research and Development Activities
• Product Developmental Activities

Preclinical Stage Products

• Comparative Analysis

Discovery Stage Products

• Comparative Analysis

Unknown Stage Products

• Comparative Analysis

Therapeutic Assessment

• Assessment by Product Type
• Assessment by Stage and Product Type
• Assessment by Route of Administration
• Assessment by Stage and Route of Administration
• Assessment by Molecule Type
• Assessment by Stage and Molecule Type

Clinical Trial Assessment

Clinical Trial Analysis

• Assessment by Status
• Assessment by Status and Phase of development
• Assessment by End Point Status
• Assessment by Enrolled Patients by Age
• Assessment by Study Completion Year

Clinical Trial Design Analysis

• Assessment by Allocation of Clinical Trials
• Assessment by Interventional Model of Clinical Trials
• Assessment by Enrolled Patients by Status
• Assessment by Masking of Clinical Trials

Sponsor and Geographical Analysis

• Assessment by Top Sponsors
• Assessment by Total Trials Sponsored by Countries and Phase
• Assessment by Clinical Therapies by Countries

Inactive Products

• Comparative Analysis

Obstructive Sleep Apnea- Unmet needs

Obstructive Sleep Apnea - Market drivers and barriers

List of Tables

• Table 1 Total Products for Obstructive Sleep Apnea
• Table 2 Late Stage Products
• Table 3 Mid Stage Products
• Table 4 Early Stage Products
• Table 5 Pre-clinical & Discovery Stage Products
• Table 6 Assessment by Product Type
• Table 7 Assessment by Stage and Product Type
• Table 8 Assessment by Route of Administration
• Table 9 Assessment by Stage and Route of Administration
• Table 10 Assessment by Molecule Type
• Table 11 Assessment by Stage and Molecule Type
• Table 12 Assessment by Status
• Table 13 Assessment by Status and Phase
• Table 14 Assessment by End Point Status
• Table 15 Assessment of Enrolled Participants by Age
• Table 16 Assessment by Study Completion Year
• Table 17 Assessment by Primary Purpose of Clinical Trials
• Table 18 Assessment by Allocation of Clinical Trials
• Table 19 Assessment by Interventional Model of Clinical Trials
• Table 20 Assessment by Masking of Clinical Trials
• Table 21 Assessment by Enrolled participants by Status
• Table 22 Assessment by Top Sponsors
• Table 23 Assessment by Countries and Stage of Development
• Table 24 Inactive Products

List of Figures

• Figure 1 Total Products for Obstructive Sleep Apnea
• Figure 2 Late Stage Products
• Figure 3 Mid Stage Products
• Figure 4 Early Stage Products
• Figure 5 Preclinical and Discovery Stage Products
• Figure 6 Assessment by Product Type
• Figure 7 Assessment by Stage and Product Type
• Figure 8 Assessment by Route of Administration
• Figure 9 Assessment by Stage and Route of Administration
• Figure 10 Assessment by Molecule Type
• Figure 11 Assessment by Stage and Molecule Type
• Figure 12 Assessment by Status
• Figure 13 Assessment by Status and Phase
• Figure 14 Assessment by End Point Status
• Figure 15 Assessment of Enrolled Participants by Age
• Figure 16 Assessment by Study Completion Year
• Figure 17 Assessment by Primary Purpose of Clinical Trials
• Figure 18 Assessment by Allocation of Clinical Trials
• Figure 19 Assessment by Interventional Model of Clinical Trials
• Figure 20 Assessment by Masking of Clinical Trials
• Figure 21 Assessment by Enrolled participants by Status
• Figure 22 Assessment by Top Sponsors
• Figure 23 Assessment by Countries and Stage of Development
• Figure 24 Inactive Products